TGFB1 and Duchenne muscular dystrophy: Despite major progress in characterizing the biochemical mechanisms of TGF-β activation, the pathomechanisms underlying the sustained activation of latent TGF-β3 in DMD fibrotic diseases remain incompletely understood.